Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03889574 · ClinicalTrials.gov registry record

Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization

A clinical trial of Cardiac Disease, sponsored by Methodist Health System.

Completed
Registry status
84
Enrollment target
1
Study location

NCT03889574: Completed study of Cardiac Disease, sponsored by Methodist Health System.

NCT03889574 is a study of Cardiac Disease that has completed, run by Methodist Health System. The registered enrollment target is 84 participants, below the 819-participant average among 24 other Cardiac Disease trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03889574, a study of Cardiac Disease, has completed, sponsored by Methodist Health System.

COMPLETED
Registry status
84 participants
Enrollment target
1
Study location

Study Summary

Aim(s)/Objective(s) * To evaluate the safety and efficacy of triple antithrombotic therapy in patients taking DAPT of aspirin and a P2Y12 inhibitor in addition to either a NOAC or warfarin for the prevention of thromboembolic or acute coronary syndrome (ACS) events in patients with non-valvular atrial fibrillation (AF), history of coronary artery disease (CAD)/stent placement or recurrent ACS event. * To determine the Methodist Health System (MHS) prescribing practices and patterns in cardiac patients with a history of AF who are admitted for CAD or an ACS event requiring PCI. Hypothesis Primary Hypothesis Cardiac patients with a history of AF and an indication for long-term NOAC who are also prescribed DAPT following an ASC event or revascularization with stenting will demonstrate a significant difference in cardiovascular outcomes and major bleeding events when compared with warfarin-based triple therapy.

Primary Outcome

To compare the incidence of MACE, stroke (ischemic and hemorrhage), MI (STEMI and NSTEMI), stent thrombosis, systemic embolism (VTE), death (all-cause, cardiac and non-cardiac) and CAD-associated hospitalizations/ED visits) in patients who received warfarin-based triple therapy versus NOAC-based triple therapy.

Conditions Studied

Study Locations (1)

Texas

  • Methodist Dallas Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2019-02-26
Est. Completion 2019-06-27
Methodist Health System

125 total trials

What the finished NCT03889574 record still lists

NCT03889574 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 819-participant average among 24 other Cardiac Disease trials with a reported enrollment target (90% lower).

The record links to 1 condition, with Cardiac Disease appearing as the primary indexed condition, and to 0 interventions.

NCT03889574 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT03889574 about?

NCT03889574 is a clinical study titled "Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization". Aim(s)/Objective(s) * To evaluate the safety and efficacy of triple antithrombotic therapy in patients taking DAPT of aspirin and a P2Y12 inhibitor in addition to either a NOAC or warfarin for the prevention of thromboembolic or acute coronary syndrome (ACS) events in patients with non-valvular atr...

What is the current status of trial NCT03889574?

This trial is currently completed. The enrollment target is 84 participants. The study started on 2019-02-26. Estimated completion is 2019-06-27.

What conditions does trial NCT03889574 study?

This clinical trial studies the following conditions: Cardiac Disease.

Who is sponsoring clinical trial NCT03889574?

This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03889574 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiac Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03889574's enrollment target sits among peer trials

84 17th of 24 higher than 8 of 24 other Cardiac Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cardiac Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02391519 · 84 participants

    Effects of High Altitude on AMPK Activation

  • NCT03838536 · 84 participants · NA

    Synergistic Activity of Human Milk Nutrients and Infant Cognition

  • NCT03884075 · 84 participants · Phase 2

    Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

  • NCT03894917 · 84 participants

    Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03889574, the US trial registry maintained by the National Library of Medicine. NCT03889574 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.